Table 3.
Comparison of clinical effect of androgen deprivation therapy by prostate size
| Variable | Prostate size |
||
|---|---|---|---|
| <30 g (n=40) | 30-50 g (n=59) | >50 g (n=11) | |
| Age (yr) | 73.26±6.58 | 74.73±7.06 | 75.43±7.35 |
| Stage | |||
| T≤2 | 9 (22.5) | 12 (20.3) | 2 (18.1) |
| T≥3 | 31 (77.5) | 47 (79.7) | 9 (81.9) |
| M0 | 7 (17.5) | 10 (16.9) | 2 (18.1) |
| M1 | 33 (82.5) | 49 (83.1) | 9 (81.9) |
| Gleason score | 7.20±1.09 | 7.81±1.45 | 7.82±1.32 |
| Positive core number | 2.20±0.97 | 2.47±1.15 | 2.51±1.04 |
| PSA change (ng/mL) | -54.31±21.80 | -58.12±16.75 | -57.45±17.43 |
| Prostate volume change (%) | -37.40±4.46 | -47.55±10.11* | -48.45±11.33† |
| IPSS total score change | -4.22±1.23 | -6.56±1.76 | -7.09±2.02 |
| IPSS voiding subscore change | -2.10±0.23 | -3.76±0.68* | -4.91±0.65† |
| IPSS storage subscore change | -2.03±0.56 | -1.83±0.43 | -2.36±0.52 |
| Quality of life score change | -0.07±0.01 | -0.11±0.09 | -0.12±0.12 |
| Functional bladder capacity change (mL) | -15.75±4.34 | 17.63±6.33 | -12.78±3.76 |
| Day time voiding frequency change | -0.23±0.07 | 0.13±0.05 | -0.89±0.12 |
| Night time voiding frequency change | -0.05±0.02 | -0.03±0.01 | -0.24±0.08 |
| Qmax change (mL/sec) | 1.49±0.01 | 2.78±0.23* | 2.90±0.31† |
| Postvoid residual change (mL) | -21.81±8.37 | -29.78±7.06 | -26.83±2.95 |
Values are presented as mean±standard deviation or number (%).
PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score; Qmax, maximal uroflow rate.
*
P<0.05, <30 g vs. 30–50 g.
†
P<0.05, <30 g vs.>50 g.